COST-EFFECTIVENESS OF HLA-B*5701 PROSPECTIVE GENETIC SCREENING OF HYPERSENSITIVITY TO ABACAVIR

Kubaeva M B; Gushchina J Sh; Loskutova E E

doi:10.22159/ajpcr.2018.v11i2.22519

Authors

Kubaeva M B Department of General and Clinical Pharmacology, Medical Institute, Peoplesâ€™ Friendship University, Moscow, Russian Federation, Russian.
Gushchina J Sh Department of General and Clinical Pharmacology, Medical Institute, Peoplesâ€™ Friendship University, Moscow, Russian Federation, Russian.
Loskutova E E 2Department of Management and Economics of Pharmacy, Medical Institute Peoplesâ€™ Friendship University, Moscow, Russian Federation, Russian.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11i2.22519

Keywords:

HIV, Abacavir, HLA*5701 prospective screening, economic efficiency

Abstract

Â Â Objective: This study was conducted to evaluate the use of genetic tests, before prescribing drugs to reduce not only the level of side effects but also the costs associated with changing therapy. In this paper, the authors analyze the economic efficiency of HLA*5701 prospective screening of hypersensitivity to abacavir (ABC) in the treatment of HIV-infected patients.

Methods: A retrospective study was conducted among HIV-infected patients taking first-line antiretroviral therapy and further, based on the results obtained with the ABC-hypersensitivity reactions, analyzed the costs that affect on healthcare system.

Results: In the study group of HIV-infected patients, most of the cases belonged to a young, socially active part of the population. Among the study population of patients (n=637), 171 patients were assigned ABC-containing antiretroviral therapy. An increase in costs was found in 67% of cases when ABC-containing first-line therapy was replaced due to the occurrence of undesirable reactions.

Conclusion: The results show that, using this screening, we could reduce the costs associated with replacement therapy

Downloads

Download data is not yet available.

Author Biographies

Kubaeva M B, Department of General and Clinical Pharmacology, Medical Institute, Peoplesâ€™ Friendship University, Moscow, Russian Federation, Russian.

Department of General and Clinical Pharmacology

Gushchina J Sh, Department of General and Clinical Pharmacology, Medical Institute, Peoplesâ€™ Friendship University, Moscow, Russian Federation, Russian.

Department of General and Clinical Pharmacology

Loskutova E E, 2Department of Management and Economics of Pharmacy, Medical Institute Peoplesâ€™ Friendship University, Moscow, Russian Federation, Russian.

Department of Management and Economics of Pharmacy

References

Kauf TL, Farkouh RA, Earnshaw SR, Watson ME, Maroudas P, Chambers MG, et al. Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV. Pharmacoeconomics 2010;28:1025-39.

Castillo SA, Hernandez JE, Brothers CH. Long-term safety and tolerability of the lamivudine/abacavir combination as components of highly active antiretroviral therapy. Drug Saf 2006;29:811-26.

Yu AL. HIV and AIDS: National Guidelines/Acad. In: Pokrovsky, RV, editor. Preparation Under Aegis of Association Honey. On-in Quality. Moscow: GEOTAR-Media; 2013. p. 606.

Deepak MS, Kamath VG, Nair S, Kamath A. Does providing free anti-retroviral therapy ensure optimal adherence among people living with HIV/AIDS? Asian J Pharm Clin Res 2016;9:172-5.

Kumar AP, Parthasarathi G, Sudheer AP, Mothi SN, Swamy VH, Rao S. Incidence and risk factors of renal impairment in HIV-1 infected patients receiving tenofovirbased antiretroviral therapy in a South Indian hospital. Int J Pharm Pharm Sci 2017;9:152-5.

Max B, Sherer R. Management of the adverse effects of antiretroviral therapy and medication adherence. Clin Infect Dis 2000;28:34-46.

Wolf E, Blankenburg M, Bogner JR, Becker W, Gorriahn D, Mueller MC, et al. Cost impact of prospective HLA-B*5701 screening prior to abacavir/lamivudine fixed dose combination use in Germany. Eur J Med Res 2010;15:145-51.

Nieves Calatrava D, Calle-MartÃn Ode L, Iribarren-Loyarte JA, Rivero-RomÃ¡n A, GarcÃa-Bujalance L, PÃ©rez-Escolano I, et al. Cost-effectiveness analysis of HLA-B*5701 typing in the prevention of hypersensitivity to abacavir in HIV+ patients in spain. Enferm Infecc Microbiol Clin 2010;28:590-5.

Wolf E, Stoll M, Becker-Andre M, Bogner J, Becker W, Gorriahn D, et al. Prospective HLA-B*5701 Screening for Abacavir Hypersensitivity Saves Costs, XVII. International AIDS Conference, Mexico City, Mexico. 2008. p. 3-8.

Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2004;14:335-42.

Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: A systematic review. J Am Med Assoc 2001;286:2270-9.

Schackman BR, Scott CA, Walensky RP, Losina E, Freedberg KA, Sax PE. The cost-effectiveness of HLA B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 2008;22:2025-33.

Le PH, Tran QV, Vo TQ. A systematic review of hepatitis virus review studies: A case of health economic evaluation analysis. Int J Pharm Pharm Sci 2017;9:114-20.